Neuroprotection is provided by the CysLTR1 antagonist Montelukast and the CysLTR2 antagonist HAMI3379, as they inhibit ischemia-induced microglial activation and pro-inflammatory cytokine release (Shi et al., 2015). The gene discussed is CYSLTR2; the disease is ischemia.